A retrospective study supported the role of primary radiotherapy in early-stage follicular lymphoma.
Researchers have identified a potential new target for CAR T-cell therapy in patients with multiple myeloma.
Researchers tested the PI3K inhibitor umbralisib in patients with relapsed/refractory marginal zone lymphoma in a phase II study that was presented at the AACR Annual Meeting.
Results of the phase III ADMIRAL trial, which tested the FLT3 inhibitor gilteritinib in patients with relapsed/refractory acute myeloid leukemia, were presented at the AACR Annual Meeting.
Management of Gastrointestinal Toxicities From Ixazomib: Tips to Curb Nausea, Vomiting, Diarrhea, and Constipation
An oncology pharmacist discusses how to manage GI toxicities in multiple myeloma patients.
Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.
The FDA has granted Priority Review to Celgene’s application for lenalidomide in combination with rituximab for previously untreated follicular lymphoma.
The phase III COLUMBA study compared a subcutaneous formulation of daratumumab vs the intravenous form in patients with relapsed or refractory multiple myeloma.
A recent study evaluated whether living in an industrial city could be an important risk factor for developing AML.
Although many immunotherapies for AML have been explored, none have ever been shown to reduced relapse rates.